Intra-Cellular Therapies, Inc.
(NASDAQ : ITCI)

( )
ITCI PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.45%201.801.2%$542.05m
GILDGilead Sciences, Inc.
-1.21%73.270.9%$465.10m
BIIBBiogen Inc.
-2.95%320.411.3%$380.15m
CELGCelgene Corporation
-0.65%82.411.2%$337.48m
ILMNIllumina, Inc.
-2.60%313.103.5%$332.96m
REGNRegeneron Pharmaceuticals, Inc.
-1.36%389.832.6%$235.91m
VRTXVertex Pharmaceuticals Incorporated
-1.79%175.691.9%$230.46m
ALXNAlexion Pharmaceuticals, Inc.
-0.53%125.892.0%$220.48m
SRPTSarepta Therapeutics, Inc.
-3.30%134.2216.4%$169.84m
AAgilent Technologies, Inc.
-1.95%64.471.5%$159.28m
BMRNBioMarin Pharmaceutical Inc.
-0.58%103.224.4%$142.60m
LGNDLigand Pharmaceuticals Incorporated
-4.84%187.5223.3%$115.84m
EXASExact Sciences Corporation
-2.88%61.6425.3%$102.69m
NKTRNektar Therapeutics
-2.76%48.195.6%$101.86m
NBIXNeurocrine Biosciences, Inc.
-2.24%112.015.1%$98.21m

Company Profile

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard on August 29, 2013 and is headquartered in New York, NY.